Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 25)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Doxycycline |
Approved, Investigational, Vet_approved |
Phase 3 |
|
564-25-0 |
54671203 |
Synonyms:
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
5-Hydroxy-a-6-deoxytetracycline
5-Hydroxy-alpha-6-deoxytetracycline
5-Hydroxy-α-6-deoxytetracycline
6a-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
6alpha-Deoxy-5-oxytetracycline
6Α-deoxy-5-oxytetracycline
Anhydrous doxycycline
BMY-28689|Monodox®|Vibramycin®
Doxcycline anhydrous
Doxiciclina
DOXY
Doxychel
Doxycyclin
Doxycycline
|
Doxycycline (anhydrous)
DOXYCYCLINE ANHYDROUS
DOXYCYCLINE HCL
Doxycycline hyclate
Doxycycline hydrate
Doxycycline hydric acid
Doxycycline monohydrate
Doxycycline monohydric acid
Doxycyclinum
Doxytetracycline
GS-3065
Jenacyclin
Monodox
Oracea
Supracyclin
Vibramycin
|
|
2 |
|
Artenimol |
Approved, Experimental, Investigational |
Phase 3 |
|
71939-50-9 |
540327 |
Synonyms:
3alpha-Hydroxydeoxydihydroartemisinin
8alpha-Hydroxydeoxyartemisinin
9alpha-Hydroxydeoxyartemisinin
ARTEMETHER RELATED COMPOUND A
ARTENIMOL
beta-Dihydroartemisinin
DIHYDROARTEMISININ
|
Dihydroartemisinine
Dihydroqinghaosu
Dihydroquinghaosu
Dihydroquinghaosu, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12alpha,12ar*))-isomer
Dihydroquinghaosu, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12alpha,12ar*))-isomer
GNF-PF-5634
|
|
3 |
|
Piperaquine |
Approved, Experimental, Investigational |
Phase 3 |
|
4085-31-8 |
|
Synonyms:
1,3-Bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane
1,3-Bis(4-(7'-chloro-4'-quinoline)-1-piperazine)
1,3-Bis[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propane
|
PIPERAQUINE
Piperaquinoline
|
|
4 |
|
Sodium citrate |
Approved, Investigational |
Phase 3 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
5 |
|
Diethylcarbamazine |
Approved, Investigational, Vet_approved |
Phase 3 |
|
90-89-1 |
3052 |
Synonyms:
Aventis brand OF diethylcarbamazine citrate
Camin
Carbamazine
Carbilazine
Citrate, diethylcarbamazine
Diethyl carbamazine
Diethylcarbamazin
Diethylcarbamazine
Diéthylcarbamazine
Diethylcarbamazine citrate
Diethylcarbamazine citrate (1:1)
Diethylcarbamazine citrate (1:2)
Diethylcarbamazine L-tartrate (1:1)
Diethylcarbamazine maleate
|
Diethylcarbamazine monohydrochloride
Diethylcarbamazine phosphate (1:1)
Diethylcarbamazinum
Dietilcarbamazina
Ditrazine base
Ethodryl
Hetrazan
Loxuran
Maleate, diethylcarbamazine
Monohydrochloride, diethylcarbamazine
N,N-Diethyl-4-methyl-1-piperazinecarboxamide
N,N-Diethyl-4-methylpiperazine-1-carboxamide
Notezine
|
|
6 |
|
Moxidectin |
Approved, Investigational, Vet_approved |
Phase 3 |
|
113507-06-5 |
72728820 |
Synonyms:
5-Hydroxymilbemycin beta7
CL-301,423
CL-301423
Cydectin
Milbeknock
Milbemectin
Milbemycin a3
Milbemycin a4
Milbemycin alpha1
Milbemycin alpha10
Milbemycin alpha11
Milbemycin alpha13
Milbemycin alpha14
Milbemycin alpha15
Milbemycin alpha2
Milbemycin alpha3
Milbemycin alpha4
|
Milbemycin alpha5
Milbemycin alpha6
Milbemycin alpha7
Milbemycin alpha8
Milbemycin alpha9
Milbemycin b
Milbemycin beta1
Milbemycin beta12
Milbemycin beta2
Milbemycin beta3
Milbemycin D
Milbemycins
Mixture OF milbemycins a3 and a4
MOXIDECTIN
Moxidectina
Moxidectinum
|
|
7 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
8 |
|
Antimalarials |
|
Phase 3 |
|
|
|
9 |
|
Citrate |
|
Phase 3 |
|
|
|
10 |
|
Praziquantel |
Approved, Investigational, Vet_approved |
Phase 1 |
|
55268-74-1 |
4891 |
Synonyms:
8440, EMBAY
Bayer brand OF praziquantel
Biltricide
Cesol
CESTOCUR
Cisticid
Cysticide
Droncit
Drontsit
EMBAY 8440
|
EMBAY-8440
Merck brand OF praziquantel
Prasiquantel
PRAZIQUANTEL
Praziquantel, (+-)-isomer
Praziquantel, (R)-isomer
Praziquantel, (S)-isomer
Pyquiton
Traziquantel
|
|
11 |
|
Benzimidazole |
Experimental, Investigational |
Phase 1 |
|
51-17-2 |
5798 |
Synonyms:
1,3-Benzodiazole
1,3-Diazaindene
1H-BENZIMIDAZOLE
1H-BENZO[D]IMIDAZOLE
1H-BENZOIMIDAZOLE
Azindole
Benzimidazole
|
Benzimidazole monohydrochloride
Benzimidazole mononitrate
Benzoglyoxaline
Hbim
Hbzim
O-Benzimidazole
|
|
12 |
|
Oxfendazole |
Investigational, Vet_approved |
Phase 1 |
|
53716-50-0 |
40854 |
Synonyms:
(5-(Phenylsulfinyl)-1H-benzimidazol-2-yl)carbamate methyl ester
(5-(Phenylsulfinyl)-1H-benzimidazol-2-yl)carbamic acid methyl ester
(5-(Phenylsulphinyl)-1H-benzimidazol-2-yl)carbamate methyl ester
(5-(Phenylsulphinyl)-1H-benzimidazol-2-yl)carbamic acid methyl ester
5-(Phenylsulfinyl)-2-benzimidazolecarbamate methyl ester
5-(Phenylsulfinyl)-2-benzimidazolecarbamic acid methyl ester
5-(Phenylsulphinyl)-2-benzimidazolecarbamate methyl ester
5-(Phenylsulphinyl)-2-benzimidazolecarbamic acid methyl ester
5-Phenylsulfinyl-2-carbomethoxyaminobenzimidazole
5-Phenylsulphinyl-2-carbomethoxyaminobenzimidazole
Benzelmin
FBZ-SO
Fenbendazole S-oxide
Fenbendazole sulfoxide
Fenbendazole sulphoxide
Methyl (5-phenylsulfinyl)-1H-benzimidazol-2-yl carbamate
Methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate
|
Methyl [5-(phenylsulfinyl)-1H-benzimidazol-2-yl]carbamate, 9ci
Methyl 5(6)-phenylsulfinyl-2-benzimidazolecarbamate
Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate
Methyl 5-(phenylsulfinyl)-benzimidazol-2-carbamate
Nanthic
OFDZ
Oxfendazol
Oxfendazole
Oxfendazole monohydrochloride
Oxfendazolum
Repidose
RS 8858
Synanthic
Synanthic (veterinary)
Systamex
Systemax
|
|
13 |
|
Emodepside |
Investigational, Vet_approved |
Phase 1 |
|
155030-63-0 |
|
Synonyms:
|
14 |
|
Pharmaceutical Solutions |
|
Phase 1 |
|
|
|
15 |
|
Toltrazuril |
|
Phase 1 |
|
|
|
16 |
|
Mebendazole |
Approved, Vet_approved |
|
|
31431-39-7 |
4030 |
Synonyms:
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamate methyl ester
(5-Benzoyl-1H-benzimidazol-2-yl)-carbamic acid methyl ester
Abello farmacia brand OF mebendazole
Anti worm
Anti-worm
Ardeypharm brand OF mebendazole
Bantenol
Banworm
Boots brand OF mebendazole
Boots threadworm treatment
Degort's brand OF mebendazole
Diba brand OF mebendazole
Elfar brand OF mebendazole
EMVERM
Esteve brand OF mebendazole
Healthypharm brand OF mebendazole
Janssen brand OF mebendazole
Leidapharm brand OF mebendazole
Lomper
Madicure
MBDZ
Mebendan
Mebendazol
Mebendazole
|
Mébendazole
MEBENDAZOLE POLYMORPH C
Mebendazolum
Mebenvet
Norgine brand OF mebendazole
NSC-184849
OVEX
Pfizer brand OF mebendazole
Pripsen mebendazole
R-17635
Sqworm
SSL Brand OF mebendazole
Streger brand OF mebendazole
Sufil
Surfont
Taxandria brand OF mebendazole
Tedec meiji brand OF mebendazole
Telmin
TELMINTIC
Vermicol
Vermidil
Vermin
Vermox
Wormkuur
|
|
17 |
|
Piperazine |
Approved, Vet_approved |
|
|
110-85-0 |
4837 |
Synonyms:
1,4 Diazacyclohexane
1,4 Piperazine
1,4-Diazacyclohexane
1,4-Piperazine
Diethylenediamine
Diethyleneimine
Fluphenazine dihydrochloride
Hexahydropyrazine
Piperazidine
Piperazin
Piperazina
Piperazine
Piperazine diacetate
Piperazine dihydrochloride
Piperazine hexahydrate
|
Piperazine hydrate
Piperazine hydrobromide
Piperazine hydrochloride
Piperazine monohydrochloride
Piperazine phosphate
Piperazine phosphate (1:1)
Piperazine phosphate anhydrous
Piperazine salt
Piperazine sulfate
Piperazine tartrate
Piperazine tartrate (1:1), (R-(r*,r*))-isomer
Piperazine tartrate, (R-(r*,r*))-isomer
Piperazinium oleate
Pripsen
Vermizine
|
|
18 |
|
Permethrin |
Approved, Investigational |
|
|
52645-53-1 |
40326 |
Synonyms:
(3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
(3-Phenoxyphenyl)methyl (+-)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylic acid
(3-Phenoxyphenyl)methyl (±)-cis,trans-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropanecarboxylate
(m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate
3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropane carboxylate, (3-phenoxyphenyl) methyl ester
3-(2,2-Dichloroethenyl)-2,2-dimethylcyclopropane carboxylic acid, (3-phenoxyphenyl) methyl ester
3-Phenoxybenzyl-(+-)-cis,trans-2,2-dichlorovinyl-2,2-dimethyl-cyclopropylcarboxylic acid, ester
3-Phenoxybenzyl-cis,trans-(1Rs)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate
Ambush
cis Permethrin
cis-(1Rs)-Permethrin
cis-Permethrin
Cyclopropanecarboxylic acid, 3-(2,2-dichloroethenyl)-2,2-dimethyl-, (3-phenoxyphenyl)methyl ester
Elimite
LYCLEAR
LYTHRIN
Nittifor
NIX
NRDC 143
|
NRDC 147
NRDC143
NRDC-143
NRDC147
NRDC-147
PERMETHRIN
Permethrin, (1R-cis)-isomer
Permethrin, (1R-trans)-isomer
Permethrin, (1S-cis)-isomer
Permethrin, (1S-trans)-isomer
Permethrin, (cis-(+-))-isomer
Permethrin, (cis)-isomer
Permethrin, (trans-(+-))-isomer
Permethrin, (trans)-isomer
Permethrin, cis-(1Rs)-isomer
Permethrin, trans-(1Rs)-isomer
trans Permethrin
trans-(1Rs)-Permethrin
trans-Permethrin
|
|
19 |
|
Calcium, Dietary |
|
|
|
|
|
20 |
|
Anticoagulants |
|
|
|
|
|
21 |
|
Piperazine citrate |
|
|
|
|
|
22 |
|
DMP 777 |
|
|
|
157341-41-8 |
|
23 |
|
Chelating Agents |
|
|
|
|
|
24 |
|
Liver Extracts |
|
|
|
|
|
25 |
|
Calcium |
Nutraceutical |
|
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
Interventional clinical trials:
(show all 47)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali |
Completed |
NCT02784743 |
Phase 4 |
''albendazole'' and ''ivermectin'' |
2 |
Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations |
Completed |
NCT03036059 |
Phase 4 |
400 μg/kg Ivermectin + 400 mg Albendazole |
3 |
Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial |
Completed |
NCT03570814 |
Phase 4 |
Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15 |
4 |
AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole |
Withdrawn |
NCT01903057 |
Phase 4 |
azithromycin;ivermectin;albendazole;placebo |
5 |
A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection |
Completed |
NCT02927496 |
Phase 3 |
Doxycycline;Placebo |
6 |
A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection |
Completed |
NCT02929134 |
Phase 3 |
Doxycycline;Placebo |
7 |
A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection |
Completed |
NCT02929121 |
Phase 3 |
Doxycycline;Placebo |
8 |
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study |
Completed |
NCT02509481 |
Phase 2, Phase 3 |
Ivermectin;Albendazole |
9 |
A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases |
Completed |
NCT03676140 |
Phase 3 |
Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8 |
10 |
Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) DeWorm3 Project |
Recruiting |
NCT03014167 |
Phase 3 |
Albendazole |
11 |
Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial |
Recruiting |
NCT04844905 |
Phase 3 |
Ivermectin;Placebo;Dihydroartemisinin-piperaquine |
12 |
A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis |
Active, not recruiting |
NCT04410406 |
Phase 3 |
Ivermectin;Diethylcarbamazine;Albendazole;Moxidectin |
13 |
Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline |
Completed |
NCT00340691 |
Phase 2 |
Doxycycline |
14 |
Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa |
Completed |
NCT01975441 |
Phase 2 |
Diethylcarbamazine;Albendazole;Ivermectin |
15 |
Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study |
Completed |
NCT00511004 |
Phase 2 |
Albendazole;Diethylcarbamazine |
16 |
Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study |
Completed |
NCT00375583 |
Phase 2 |
DEC/Albendazole |
17 |
A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases |
Completed |
NCT03664063 |
Phase 2 |
Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine |
18 |
Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study |
Completed |
NCT00339417 |
Phase 2 |
Albendazole;Ivermectin |
19 |
A Phase 1, Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of an Oxfendazole Tablet Formulation in a Randomized, Double-Blind, Placebo-Controlled Design After Single and Multiple Oral Dosing in Healthy Adult Volunteers |
Completed |
NCT04920292 |
Phase 1 |
Oxfendazole;Placebo |
20 |
A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects |
Completed |
NCT03383614 |
Phase 1 |
LSF emodepside (BAY 44-4400) or matching placebo |
21 |
Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects |
Completed |
NCT03383523 |
Phase 1 |
Emodepside (BAY 44-4400) |
22 |
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire |
Completed |
NCT02845713 |
Phase 1 |
Ivermectin, Diethylcarbamazine Albendazole (IDA) |
23 |
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug |
Not yet recruiting |
NCT05084560 |
Phase 1 |
AWZ1066S;Placebo |
24 |
Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis |
Unknown status |
NCT04258670 |
|
|
25 |
Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia |
Unknown status |
NCT03683745 |
|
|
26 |
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia |
Completed |
NCT01905436 |
|
Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration |
27 |
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis |
Completed |
NCT01905423 |
|
Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual) |
28 |
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast |
Completed |
NCT02032043 |
|
Annual versus Semiannual Albendazole plus Ivermectin MDA |
29 |
Research for Elimination of Lymphatic Filariasis (ICIDR) |
Completed |
NCT00406627 |
|
|
30 |
Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators |
Completed |
NCT03352206 |
|
2 drug dose - DA;3 drug dose - IDA |
31 |
Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] |
Completed |
NCT02974049 |
|
Albendazole;Ivermectin;Diethylcarbamazine |
32 |
Research for Elimination of Human Filariasis |
Completed |
NCT00145223 |
|
|
33 |
Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis |
Completed |
NCT00139100 |
|
antimicrobial agent in soap |
34 |
Exhaled NO Testing in Filariasis |
Completed |
NCT01628497 |
|
|
35 |
Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji |
Completed |
NCT03177993 |
|
3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA |
36 |
Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India |
Completed |
NCT01629771 |
|
|
37 |
Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine |
Completed |
NCT00295698 |
|
Diethylcarbamazine |
38 |
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea |
Completed |
NCT03268252 |
|
|
39 |
A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali |
Completed |
NCT01586169 |
|
triple co administration at once of the combination of Albendazole + ivermectin + azithromycin |
40 |
Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis |
Completed |
NCT02899936 |
|
3 drug dose - IDA;2 drug dose - DA |
41 |
Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications |
Completed |
NCT00471666 |
|
|
42 |
Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis |
Completed |
NCT01547884 |
|
|
43 |
Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas |
Completed |
NCT03131401 |
|
|
44 |
Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection |
Completed |
NCT00344279 |
|
|
45 |
When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to |
Recruiting |
NCT04124250 |
|
|
46 |
Host Response to Infection and Treatment in the Filarial Diseases of Humans |
Recruiting |
NCT00001230 |
|
|
47 |
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study |
Terminated |
NCT01213576 |
|
Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;albendazole 800mg and ivermectin 400mcg/kg bi-annually |
Cochrane evidence based reviews: filariasis
|